

1

Introduction

2

Executive summary

3

Research areas and groups

4

Associated clinicians



3.2.1 Research on Invasive Clinical and Translational Cardiology - ICCIT-PAZ

Publications: 125 | Q1:82

COMPOSITION

José Raúl Moreno Gómez.

Jefe de Servicio de Cardiología. Hospital Universitario La Paz

María Fernández Velasco.

Investigadora Senior (Contrato Miguel Servet-Tipo I). Jefa de Laboratorio. FIBHULP

- **Joaquín Jesús Alonso Martín.** Jefe de Servicio de Cardiología. Hospital Universitario Getafe
- **Isabel Antorrena Miranda.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Eduardo Armada Romero.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Paula Awamleh García.** Facultativo Especialista de Área en Cardiología. Hospital Universitario Getafe
- **Andrea Bueno Sen.** Investigadora Predoctoral. FIBHULP
- **Paula Cantolla Pablo.** Investigadora Predoctoral. FIBHULP
- **Juan Caro Codón.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Almudena Castro Conde.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Regina Dalmau González-Gallarza.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Francisco Javier Domínguez Melcón.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Carlos Escobar Cervantes.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **María Jesús Espinosa Pascual.** Facultativo Especialista de Área en Cardiología. Hospital Universitario Getafe
- **Jaime Fernández de Bobadilla Osorio.**

Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

- **Lucía Fernández Gasso.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Alfonso Fraile Sanz.** Facultativo Especialista de Área en Cardiología. Hospital Universitario Getafe
- **Javier Fuertes Beneítez.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Guillermo Galeote García.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Marta Gil Fernández.** Investigadora Predoctoral. IIB Sols-Morreale
- **Elvira Ana González García.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Teresa González Gallego.** Investigadora Senior (Contrato Ramón y Cajal). IIB Sols-Morreale
- **Gabriela Guzmán Martínez.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Ángel Manuel Iniesta Manjavacas.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Bárbara Izquierdo Coronel.** Facultativo Especialista de Área en Cardiología. Hospital Universitario de Getafe
- **Santiago Jiménez Valero.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Alfonso Jurado Román.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Teresa López Fernández.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Esteban López de Sá y Areses.** Jefe de Sección de Cuidados Intensivos Cardiológicos. Hospital Universitario La Paz
- **José Luis López-Sendón Hentschel.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz



- **José Luis Merino Llorens.** Facultativo Especialista de Área en Cardiología. Director Unidad Investigación en Arritmias/Electrofisiología Robótica. Hospital Universitario La Paz
- **Pablo Merás Colunga.** Médico Adjunto Cardiología. Hospital Universitario La Paz
- **María del Mar Moreno Yangüela.** Jefe de Sección de Imagen Cardíaca. Hospital Universitario La Paz
- **Martín Negreira Caamaño.** Facultativo Especialista de Área en Cardiología. Hospital Universitario de Getafe
- **Rene Olsen Rodríguez.** Médico Interno Residente. Hospital Universitario de Getafe
- **Rafael Peinado Peinado.** Jefe de Sección de Arritmias y Electrofisiología. Hospital Universitario La Paz
- **Jesús Ángel Perea Egido.** Facultativo Especialista de Área en Cardiología. Hospital Universitario de Getafe
- **Esther Pérez David.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Inés Ponz de Antonio.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Patricia Prieto Chinchilla.** Profesora Contratada Doctora. Universidad Complutense de Madrid

- **Elsa Prieto Moriche.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Elena Refoyo Salicio.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Juan Ramón Rey Blas.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Luis Riera del Moral.** Facultativo Especialista de Área en Angiología y Cirugía Vascular. Hospital Universitario La Paz/Profesor Asociado Departamento de Cirugía. Universidad Autónoma de Madrid
- **Adriana Rodríguez Chaverri.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Inmaculada Roldán Rabadán.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Sandra Rosillo Rodríguez.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **José Ruiz Cantador.** Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz
- **Silvia Cayetana Valbuena López.** Médico Interno Residente en Cardiología. Hospital Universitario La Paz



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

STRATEGIC OBJETIVES

- The group is made up of the different care units of the Cardiology Service of the La Paz Hospital: Clinic/Coronary Unit, Interventional Cardiology, Cardiac Imaging, Electrophysiology, Rehabilitation and Congenital Heart Disease in Adults.
- The main lines of research focus on providing clinical answers, with direct participation in international multicenter clinical trials and registries. In turn, the translational aspect is strengthened through an institutional relationship with the CNIC (Spanish National Cardiovascular Research Center)
- Dr. José Raúl Moreno Gómez, MD, PhD. Head of the Cardiology Department, HULP. Director of the ICCIT-IdiPAZ Group. Coordinator of the Cardiovascular Research Area, IdiPAZ
- The clinical arm of the ICCIT-IdiPAZ group comprises a team of cardiologists who conduct significant clinical research across various areas of cardiovascular disease. This includes research on the pathophysiology and treatment of acute coronary syndromes, new non-invasive cardiac imaging techniques, the treatment of cardiac arrhythmias, congenital heart disease, hereditary heart disease, cardiotoxicity from antineoplastic drugs, new treatments for heart failure, and new drugs for cardiovascular prevention. This research group is part of international cardiovascular research networks, which translates, among other things, into participation in numerous international clinical trials and publication in high-impact journals.
- Dr. María Fernández Velasco, PhD. Head of the Cardiac Pathophysiology Laboratory at IdiPAZ. Co-Director of the ICCIT-IdiPAZ Group. Coordinator of the Cardiovascular Research Area at IdiPAZ.
- The translational section of the group is led by Dr. María Fernández Velasco. Her multidisciplinary translational group comprises young basic and clinical researchers who study how key factors of the innate immune system are involved in the development of some of the most prevalent cardiac pathologies worldwide and in Spain, such as acute myocardial infarction and heart failure, as well as in less prevalent but significant pathologies such as heart transplants in patients with congenital heart disease. They are also developing a line of research in the field of immunity related to the cardiotoxic effects of antitumor treatments such as anthracyclines and immunotherapy. The development of these lines of research is made possible through close collaboration between the group and clinical researchers in the cardiology departments of various public hospitals and, fundamentally, through the group's integration into the cardiology department of La Paz University Hospital. Furthermore, the group has international collaborations that also contribute to the development, scope, and impact of its work. View publications: <https://pubmed.ncbi.nlm.nih.gov/?term=Fernandez-Velasco%2C+M&sort=date>

RESEARCH LINES

- Myocardial ischemia. Acute and chronic. Diagnosis, prognosis, and treatment. Post-cardiac arrest hypothermia. Line Manager: José Raúl Moreno Gómez
- Cardiovascular prevention strategies.
- Cardiac arrhythmias. Catheter navigation systems. Diagnosis and treatment.
- Heart failure. Diagnosis and treatment. Cardiotoxicity and antineoplastic agents
- Cardiac imaging diagnosis
- Valvular pathologies. Diagnosis and treatment
- Congenital heart disease in adults
- Translational research in cardiology. Search for new biomarkers and molecular mechanisms involved in the most prevalent cardiac pathologies. Research line leader: María Fernández Velasco

RESEARCH ACTIVITY

Doctoral Theses

- **Rivero Santana B.** Inflamación y Remodelado Ventricular Adverso tras el Infarto Agudo de Miocardio: Papel del Inflammasoma NLRP3[dissertation]. Madrid: UAM: 2025(21/02/2025). Director: Jurado Román A, Fernández Velasco M.

Master Theses

- **Segovia Herreras D.** Evaluación de los pacientes de Cardiología bajo tratamiento con iPSC9 en la isla de Lanzarote[dissertation]. Murcia: UCAM: 2025(20/02/2025). Director: Dalmau González-Gallarza R.
- **Jiménez Baena E.** Seguimiento clínico de pacientes con cardiopatía isquémica sometidos a nueva angioplastia[dissertation]. Murcia: UCAM: 2025(20/02/2025). Director: Dalmau González-Gallarza R.

Publications

- **Alfonso F, Shaburishvili T, Farah B, Gogorishvili I, Monsegu J, Baranauskas A, Bressollette E, Shaburishvili G, Cuesta J, Rivero F, Moreno R, Sabate M.** First-in-man study of a novel everolimus-coated balloon for the treatment of coronary in-stent restenosis. *Coronary Artery Dis.* 2025; 36(2): 91-8. Article. IF: 2.2; Q3
- **Althoff TF, Anderson RH, Goetz C, Petersen SE, Díaz PM, Nijveldt R, Maurovich-Horvat P, Bax J, Hussain S, Schmidt C, Spicer DE, Sánchez-Quintana D, Corsi C, Dössel O, Climent AM, Rodríguez B, Schotten U, Loewe A, Guillem MS, Cabrera JA, Merino JL, Wijnmaalen AP, Bertrand PB, de Groot N, Derval N, Didenko M, Donal E, Dweck MR, Ho SY.** Regionalization of the atria for 3D electroanatomical mapping, cardiac imaging, and computational modelling: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Cardiovascular Imaging of the ESC. *Europace.* 2025; 27(7): euaf134. Article. IF: 10.2; D1
- **Ameri P, Lyon AR, Fernández TL.** ESC cardiology conference hits the ground running. *Eur Heart J.* 2025; 46(42): 4354-5. News Item. IF: 45.3; D1

- **Andrés E, Escobar C, Doi K.** Machine Learning and Artificial Intelligence in Clinical Medicine-Trends, Impact, and Future Directions. *J Clin Med.* 2025; 14(22): 8137. Editorial Material. IF: 3.3; Q1
- **Arenillas C, Celada L, Ruiz-Cantador J, Calsina B, Datta D, García-Galea E, Fasani R, Moreno-Cárdenas AB, Alba-Linares JJ, Miranda-Barrio B, Martínez-Montes AM, Álvarez-Escola C, Lecumberri B, García AG, Flores SK, Esquivel E, Ding YL, Peitzsch M, Robles-Guirado JA, Zapata RMR, Pozo-Krelinger JJ, Iglesias C, Dwight T, Muir CA, Oleaga A, Rodríguez-Monte MEGL, Del Cerro MJ, Martínez-Bendayán I, Álvarez-González E, Cubiella T, Lourenço DM Jr, Pereira MAA, Burnichon N, Buffet A, Broberg C, Dickson PV, Fraga MF, Pendás JLL, Soriano JR, Fuentes FB, Toledo SPA, Clifton-Bligh R, Dienstmann R, Villanueva J, Capdevila J, Gimenez-Roqueplo AP, Favier J, Nuciforo P, Young WF Jr, Bechmann N, Opatowsky AR, Vaidya A, Bancos I, Weghorn D, Robledo M, Casteràs A, Dos-Subirá L, Adameyko I, Chiara MD, Dahia PLM, Toledo RA.** Convergent genetic adaptation in human tumors developed under systemic hypoxia and in populations living at high altitudes. *Cancer Discov.* 2025; 15(5): 1037-62. Article. IF: 29.5; D1
- **Aznar MC, Bergler-Klein J, Boriani G, Cutter DJ, Hurkmans C, Levis M, López-Fernández T, Lyon AR, Maraldo MV.** Perfect is the enemy of good: Reply to Struikmans et al. *Radiother Oncol.* 2025; 202: 110585. Letter. IF: 5.8; Q1
- **Basile M, Gómez-Menchero A, Rivero-Santana B, Amat-Santos IJ, Jiménez-Valero S, Caballero-Borrego J, Ojeda S, Miñana G, González-García A, Tébar-Márquez D, Roa-Garrido MJ, Camacho-Freire S, Ocaranza-Sánchez R, Domínguez A, Galeote G, Moreno R, Jurado-Román A.** Rotational atherectomy, lithotripsy, or laser for calcified coronary stenosis: one-year outcomes from the Roller Coaster-EPIC22 Trial. *Catheter Cardio Int.* 2025; 106(1): 702-10. Article. IF: 1.9; Q3
- **Basile M, Jiménez-Valero S, De la Osa G, Rivero-Santana B, Zubiaur-Zamacola J, Tebar-Márquez D, González-García A, Galeote G, Jurado-Román**



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

- A, Moreno R. Thrombectomy and stenting for svc thrombosis in a post-heart transplant patient with congenital heart disease. *JACC Case Rep*. 2025; 30(40): 105856. Article. Not Indexed
- Beiert T, Knappe V, Zietzer A, Schmidt V, Purerfellner H, Sommer P, Sohns C, Veltmann C, Steven D, Chun KRJ, Maury P, Gandjbakhch E, Laredo M, Willems S, Borlich M, Fütting A, Spittler R, Richter S, Schade A, Kuniss M, Wunderlich C, Shin DI, Meininghaus DG, Bonsels M, Reek D, Wiegand U, Bauer A, Metzner A, Eckardt L, Krahnefeld O, Sticherling C, Kühne M, Nguyen DQ, Roten L, Linz D, van der Voort P, Mulder BA, Vijgen J, Almorad A, Guenancia C, Fauchier L, Boveda S, De Greef Y, Da Costa A, Jais P, Milhem A, Jesel L, García R, Poty H, Khoeiry Z, Seitz J, Laborde J, Mechulan A, Brigadeau F, Zhao A, Saludas Y, Piot O, Ahluwalia N, Martin CA, Chen J, Antolic B, Leventopoulos G, Özcan EE, Yorgun H, Cay S, Yalin K, Botros MS, Jedrejczyk-Patej E, Inaba O, Okumura K, Ejima K, Khakpour H, Catanzaro JN, Reddy V, Natale A, Blessberger H, Yang B, Vogler J, Kuck KH, Merino JL, Keelani A, Heeger CH, Popescu SS, Tilz RR. Influence of proton pump inhibitors on the incidence and clinical course of oesophageal fistula following catheter ablation for atrial fibrillation: a subanalysis of the POTTER-AF study. *Europace*. 2025; 27(10): euaf212. Article. IF: 10.2; D1
 - Bernardino JI, Dalmáu R, Rodríguez-Torres D, Saiz-Medrano G, Fernández-Velilla M, Pinilla I, Rodríguez-Centeno J, Esteban-Cantos A, Jiménez-González M, Mata T, Ramos C, Rodés B, Estébanez M. DNA N6-methyladenine and ABCA1 methylation associations with subclinical coronary atherosclerosis in people with HIV. *Clin Epigenetics*. 2025; 17(1): 158. Article. IF: 5.7; Q1
 - Biscaglia S, Erriquez A, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, Cerrato E, Sacchetta G, Menozzi A, Amat-Santos I, Gil JLD, Ruozzi M, Barbierato M, Fileti L, Picchi A, Pavasini R, Cimaglia P, Colaiori I, Casella G, Menozzi M, Cavazza C, Caretta G, Scarsini R, D'Amico G, Vadalà G, Pilato G, Moscarella E, Tebaldi M, Campo G. Physiology-guided complete

- revascularization in older patients with myocardial infarction: three-year outcomes of a randomized clinical trial. *JAMA Cardiol*. 2025; 10(11): 1130-7. Article. IF: 15.2; D1
- Bordignon S, Mills MT, Futyma P, Sultan A, Metzner A, Migliore F, Perrotta L, Anic A, Merino JL, Purerfellner H, Chun JKR. European Heart Rhythm Association survey on the perceived severity of complications in atrial fibrillation ablation: development of a standardized scoring model. *Europace*. 2025; 27(11): euaf254. Review. IF: 10.2; D1
 - Boriani G, Brachmann J, Lewalter T, Wright DJ, Badertscher P, Gale CP, Merino JL, Purerfellner H, Lip GYH. Access and reimbursement of ambulatory cardiac monitoring across Europe. *Eur Heart J Digit Health*. 2025; 6(6): 1282-92. Review. IF: 5.3; Q1
 - Boriani G, Imberti JF, Asteggiano R, Ameri P, Mei DA, Farkowski M, Chun J, Merino JL, López-Fernández T, Lyon AR. Mobile/wearable digital devices for care of active cancer patients: a survey from the ESC Council of Cardio-Oncology. *Eur Heart J Digit Health*. 2025; 6(2): 162-9. Article. IF: 5.3; Q1
 - Camilli M, Occhipinti G, Potere N, Laudani C, Freixa X, Lombardo A, Burzotta F, Di Nisio M, Carrier M, López-Fernández T, Maurea N, Rocca B. Management of cancer-associated venous thromboembolism: Perspectives on optimizing current therapeutics with a focus on factor XI inhibition. *J Thromb Thrombolys*. 2025; 58(8): 1095-108. Review. IF: 2.1; Q3
 - Cantone A, Verardi FM, Vadalà G, Guiducci V, Casella G, Cavazza C, Cerrato E, Sacchetta G, Moreno R, Serenelli M, Santos IA, Gill JLD, Scarsini R, Picchi A, Cocco M, Colaiori I, Barbierato M, Ariotti M, Marchini F, Pavasini R, Cagliioni S, Lanzilotti V, Menozzi M, Erriquez A, Campo G, Biscaglia S. Renal function-stratified comparison of complete vs culprit-only revascularization in older patients with myocardial infarction and multivessel disease. *JACC-Cardiovasc Inte*. 2025; 18(23): 2849-59. Article. IF: 12.7; D1
 - Caro-Codón J, Castrejón S, Cadenas R, Casanova C, Vélez A, Basurte M, Lacuey G, Climent V, Salvador O, Severo-Sánchez A, Fernández L, Pérez-David E, Peinado R, Valbuena-López S,

- Guzmán G, Jiménez-Mas A, Moreno R, Merino JL. Extended ECG monitoring in patients with hypertrophic cardiomyopathy: The Tempo-HCM Study. *J Clin Med*. 2025; 14(20): 7432. Article. IF: 3.3; Q1
- Castrejón-Castrejón S, Cossiani MM, Sola NB, Roldán JDR, Criado JLI, Osca J, Roca-Luque I, Moya A, Quesada A, Olivares VMH, Castellano NP, Fernández-Gómez JM, Macías-Ruiz R, Villanueva BB, Bada NG, Torres CF, Verdejo BS, Somonte PS, Cervantes CE, Moreno R, Merino JL. High-power short-duration radiofrequency application for faster and safer pulmonary vein isolation The POWER-FAST III Trial. *JACC Clin Electrophysiol*. 2025; 11(2): 350-61. Article. IF: 7.2; Q1
 - Criado JLI, Ortiz M, García-Fernández J, Martínez-Alday JD, Font ER, Moreno J, López MA, Almor JM, Gil ML, Medina DG, Granell RR, Peinado RP, Gelizo VB, Muñoz JJS, Medina O, Díaz-Parreño SA, Criado AI, González JM, Merodio JMO, Almendral J. Can ICD electrograms help ventricular tachycardia ablation? results from the multicenter randomized AIDEG-VTA Trial. *J Am Coll Cardiol*. 2025; 85(11): 1124-37. Article. IF: 22.3; D1
 - Cuadros M, Abadía M, Castillo P, Martín-Arranz MD, Gonzalo N, Romero M, García-Sánchez A, García-Samaniego J, Oliveira A, Ruiz-Cantador J, González-Fernández O, Ponz I, Merás P, Merino C, Rodríguez-Chaverri A, Balbacid E, Froilán C. Role of transient elastography in the diagnosis and prognosis of Fontan-associated liver disease. *World J Gastroenterol*. 2025; 31(11): 103178. Article. IF: 7.7; Q1
 - Duccia C, Agostinetto E, Arecco L, Lobo-Martins S, Gitto M, Lyon AR, López-Fernández T, Dent S, Casalino G, Agarwala V, de Azambuja E. Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care. *ESMO Open*. 2025; 10(6): 105128. Review. IF: 10.6; Q1
 - de la Torre-Hernández JM, Alfonso F, Moreno R, Ojeda S, de Prado AP, Romaguera R. REC: Interventional cardiology is now indexed in PubMed Central, the ultimate indexing. *REC-Interv Cardiol*. 2025; 7(4): 195-201. Editorial Material. IF: 1.5; Q3

- del Prado-Montero J, Guevara-Martínez J, Cantero-Cid R, Mata-Martínez P, Cueto EJ, Lozano-Rodríguez R, Terrón-Arcos V, Abad-Moret R, Díaz-Serrano E, de Diego RP, Fernández-Velasco M, del Fresno C, Hurtado-Navarro L, López-Collazo E. Age-stratified circulating immune signatures reveal non-invasive biomarkers for colorectal cancer detection. *Immun Ageing*. 2025; 22(1): 40. Article. IF: 8.3; D1
- d'Entremont MA, Cheema Z, Pitt B, Kedev S, Cornel JH, Stankovic G, Moreno R, Storey R, Bossard M, Chauhan A, Montalescot G, Beygui F, Zannad F, Jolly S. Mineralocorticoid receptor antagonists in myocardial infarction patients: a systematic review and meta-analysis of randomized trials. *JACC Heart Fail*. 2025; 13(9): 102531. Article. IF: 11.9; D1
- Desteghe L, Lee G, Antoniou S, Merino JL, Neubeck L, Ross C, Svennberg E, Hendriks JM. A multidisciplinary team approach in the 2024 ESC guidelines for the management of patients with Atrial Fibrillation-what is the role of nurses and allied professionals? A Clinical Consensus Statement of the Association of Cardiovascular Nursing and Allied Professions (ACNAP) and the European Heart Rhythm Association (EHRA) of the ESC. *Eur J Cardiovasc Nur*. 2025; 24(6): 828-40. Review. IF: 5.4; D1
- Doehner W, Boriani G, Potpara T, Blomstrom-Lundqvist C, Passman R, Sposato LA, Dobrev D, Freedman B, Van Gelder IC, Glotzer T, Healey JS, Karapanayiotides T, Lip GYH, Merino JL, Ntaios G, Schnabel RB, Svendsen JH, Svennberg E, Wachter R, Haeusler KG, Camm AJ. Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association. *Europace*. 2025; 27(3): euaf019. Article. IF: 10.2; D1
- Escobar C, Aldegue X, Vivas D, Fernández SM, Caballero EG, Martín AG, Barrios V, Freixa-Pamias R. The gut microbiota and its role in the development of cardiovascular disease. *Expert Rev Cardiovasc Ther*. 2025; 23(1-2): 23-34. Review. IF: 2.5; Q2
- Escobar C, Camafort M, Fortuny E, Grymonprez M, Pérez-Cabeza AI, de Backer TL. Practical



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

comprehensive approach to current atrial fibrillation challenges: insights from an expert panel. *J Clin Med*. 2025; 14(15): 5199. Article. IF: 3.3; Q1

- Escobar C, Caravaca-Pérez P, Rodríguez JMF, Gómez-Otero I, Lozano-Bahamonde A, Pérez-Cabeza AI, Pérez-Silvestre J, Rafols C, Esteban-Fernández A. Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies. *Front Cardiovasc Med*. 2025; 12: 1644646. Review. IF: 3.0; Q2
- Escobar C, Facila L, Vidal-Pérez R, Lapeña AP, Vivas D, Martín AG, Fernández SM, Caballero EG, Barrios V, Freixa-Pamias R. Artificial intelligence: a promising tool for the clinical cardiologist. *Expert Rev Cardiovasc Ther*. 2025; 23(5): 209-23. Review. IF: 2.5; Q2
- Escobar C, Palacios B, Villarreal M, Gutiérrez M, Capel M, Hernández I, García M, Lledó L, Arenillas JF. Clinical and economic impact of a first major bleeding event in non-anticoagulated patients in Spain: a 3-year retrospective observational cohort study. *J Clin Med*. 2025; 14(4): 1377. Article. IF: 3.3; Q1
- Escobar C, Pascual-Figal D, Guiu-Segura JM, Capel M, Mallol EP, Caudron C. Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain. *BMC Health Serv Res*. 2025; 25(1): 974. Article. IF: 3.3; Q2
- Escobar C, Saldaña J, Merino JL, Peinado R. Vericiguat in patients with heart failure and implantable cardioverter-defibrillator. *Drugs Context*. 2025; 14: 2024105. Article. IF: 2.2; Q1
- Escobar-Cervantes C, Saldaña-García J, Torremocha-López A, Contreras-Lorenzo C, Lara-García A, Canales-Muñoz L, Martínez-González R, Vila-García J, Banach M. Integrating new technologies in lipidology: a comprehensive review. *J Clin Med*. 2025; 14(14): 4984. Review. IF: 3.3; Q1
- Esteban-Fernández A, Recio-Mayoral A, López-Vilella R, de Lara G, Barrantes-Castillo M, Gómez-Otero I, Nuñez-Villota J, Robles-Gamboa C, López-Aguilera J, Iniesta-Manjavacas A, Fluvio P, Pastor-Pérez F, Belarte-Tornero L, Alonso-Salinas G, Díez-Villanueva P, ERISEC Registry Researchers. Clinical profile of an unselected

population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial. *Front Cardiovasc Med*. 2025; 11: 1504427. Article. IF: 3.0; Q2

- Farkowski MM, Scherr D, Boriani G, Kazakiewicz D, Haim M, Huculeci R, Malaczynska-Rajpold K, Petersen SE, Timmis A, Traykov V, Vardas PE, Pürerfellner H, Merino JL. Arrhythmia care in ESC member countries: the 2025 ESC-EHRA atlas on heart rhythm disorders. *Europace*. 2025; 27(7): euaf124. Article. IF: 10.2; D1
- Fengsrud E, Blomström-Lundqvist C, Camm AJ, Goette A, Kowey PR, Merino JL, Piccini JP, Saksena S, Reiffel JA, Boriani G. Antiarrhythmic drug use in atrial fibrillation among different European countries - as determined by a physician survey. *Int J Cardiol Heart Vasc*. 2025; 59: 101709. Article. IF: 2.9; Q2
- Fernández MG, Sen AB, Pablo PC, Blasco AV, Hurtado GR, Delgado C, Cubillos C, Boscá L, Velasco MF. Atrial myopathy and heart failure: immunomolecular mechanisms and clinical implications. *Int J Mol Sci*. 2025; 26(17): 8210. Review. IF: 5.6; Q1
- Fernández-Olmo R, Cordero A, Oterino A, Blanco-Echevarría A, Vivas D, Escobar C, Ortega E, Torres-Fonseca M, Sánchez-Peñador C, Quiroga B, Pascual V, Martínez-Losas P, Escribano D, Freijo MD, Hernández RMS, Viana A, Freixa-Pamias R, Castro A, Doblas JGG. Planning of lipid-lowering treatment in atherosclerotic vascular disease. Consensus SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N. *Clin Investig Arterioscler*. 2025; 37(4): 500799. Article. IF: 1.9; Q3
- Gabani R, Brugaletta S, Bujak K, Pérez-Vizcayno MJ, Jiménez-Quevedo P, Arévalo V, Muñoz-García E, Trillo-Nouche R, del Valle R, Hernández JMD, Salido L, Gutiérrez E, Pan MN, Sánchez-Gila J, del Blanco BG, Moreno R, Mata RB, Oteo JF, Amat-Santos I, Regueiro A, Ten F, Nogales JM, Fernández-Noferriás E, Andraka L, Ferrer MC, Pinar E, Romaguera R, Ramón CC, Alfonso F, García-Blas S, Piñero A, Ignasi J, Mèndez RD, Bordes P, Meseguer J, Nombela-Franco L, Sabaté M. Impact of gender on in-hospital and long-term outcomes after transcatheter aortic valve implantation: an analysis of the Spanish TAVI

registry. *Rev Esp Cardiol (Engl Ed)*. 2025; 78(4): 338-46. Article. IF: 4.2; Q2

- Gale CP, Hindricks G, Nadarajah R, Tijssen J, Boveda S, Nielsen JC, Merino JL, Lenarczyk R, Taborsky M, Dagres N. Implantable cardioverter defibrillators in heart failure with reduced ejection fraction after myocardial infarction: the need for contemporary evidence. *Eur Heart J Qual Care Clin Outcomes*. 2025; 11(6): 816-24. Review. IF: 5.6; Q1
- Galeote G, Zubiaur J, Jurado-Román A, Fernández-Portales J, Romani S, Salinas P, García-Tejada J, Subinas A, Rodríguez M, Palazuelos-Molinerio J, Flores X, López M, Planas A, Arroyo E, Bastos G, Vera-Vera S, Jiménez-Valero S, Santana BR, Tebar D, González A, Moreno R. Coronary rotational atherectomy elective versus bailout in patients with severely calcified lesions and chronic renal failure (CRATER) trial. *Catheter Cardio Inte*. 2025; 106(3): 1702-12. Article. IF: 1.9; Q3
- García IA, Pérez PV, Plaza BL, Matabuena M, Moreno RMG, Milla SP, De Lucas EZ, Sánchez MCP, De Villar NGP. Continuous glucose monitoring as an alternative for cystic fibrosis related diabetes screening and diagnosis. *Diabetes Res Clin Pr*. 2025; 229: 112952. Article. IF: 4.6; Q2
- Gassó LF, David EP, Moreno R. Transgastric views: an adjunct in left atrial appendage evaluation. *Rev Esp Cardiol (Engl Ed)*. 2025; 78(3): 284-5. Editorial Material. IF: 4.2; Q2
- Ghigo A, Ameri P, Asnani A, Bertero E, de Boer RA, Farmakis D, González A, Heymans S, Ibáñez B, López-Fernández T, Lyon AR, Pollesello P, Rakisheva A, Stellos K, Streckfuss-Bömeke K, Tocchetti CG, Thum T, van der Meer P, Van Rooij E, Ponikowski P, Metra M, Rosano G, Van Linthout S. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart. *Eur J Heart Fail*. 2025; 27(6): 1028-46. Article. IF: 10.3; D1
- González-García A, Abelleira-Pardeiro C, Jiménez-Valero S, Balbacid-Domingo E, Gutiérrez-Larraya F, Moreno R. Self-made fenestrated device for closure of atrial septal defect.

Cardiovasc Interv Ther. 2025; 40(3): 725-6. Article. IF: 5.5; Q1

- González-García A, Jiménez-Valero S, Balbacid-Domingo E, Abelleira-Pardeiro C, Gutiérrez-Larraya F, Moreno R. Combined percutaneous pulmonary valve-in-valve and closure of paravalvular leak. *Cardiovasc Interv Ther*. 2025; 40(2): 449-50. Editorial Material. IF: 5.5; Q1
- Gunawardene MA, Pürerfellner H, Merino JL, Linz D, Sultan A, Scherr D, Deharo JC, Wohlmuth P, Feldhege J, Costa FM, Ribeiro S, Charitakis E, Verstrael A, Anselmino M, Szeplaki G, Simovic S, Jadczyk T, Adelino R, Katsoularis I, Liebrechts M, Tilz RR, Chun KRJ. PULSE survey: Population Survey on Knowledge, Gaps and Perception of Heart Rhythm disorders-an initiative of the Scientific Initiatives Committee of the European Heart Rhythm Association. *Europace*. 2025; 27(4): euaf032. Review. IF: 10.2; D1
- Hausvater A, Anthopoulos R, Seltzer A, Spruill TM, Spertus JA, Peteiro J, López-Sendón JL, Celutkienė J, Demchenko EA, Kedev S, Beleslin BD, Sidhu MS, Grodzinsky A, Fleg JL, Maron DJ, Hochman JS, Reynolds HR. Sex differences in psychosocial factors and angina in patients with chronic coronary disease. *J Am Heart Assoc*. 2025; 14(5): e037909. Article. IF: 6.0; Q1
- Helms Thomas M, Boriani G, Brunner-La Rocca HP, Klein C, Koehler F, Krzesinski P, Maaser Y, Neumann A, Merino JL, Schultz C, Wright DJ, Zippel-Schultz B, Hindricks G. The present and future of cardiologic telemonitoring in Europe: a statement from seven European countries. *Herzschrittmacherther Elektrophysiol*. 2025; 36(2): 138-48. Review. Not Indexed
- Herrmann J, López-Fernández T, Lyon AR. The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology. *Eur Heart J*. 2025; 46(13): 1186-8. Editorial Material. IF: 45.3; D1
- Jaén RI, Sánchez-García S, Fernández-Velasco M, Cuadrado I, de las Heras B, Boscá L, Prieto P. New biomarkers in the diagnosis and prognosis of dilated cardiomyopathy: pro-resolving lipids and miRNAs. *Cells*. 2025; 14(23): 1916. Article. IF: 6.0; Q2
- Jolly SS, d'Entremont MA, Lee SF, Mian R, Tyrwhitt J, Kedev S, Montalescot G, Cornel



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

JH, Stankovic G, Moreno R, Storey RF, Henry TD, Mehta SR, Bossard M, Kala P, Layland J, Zafirovska B, Devereaux PJ, Eikelboom J, Cairns JA, Shah B, Sheth T, Sharma SK, Tarhuni W, Conen D, Tawadros S, Lavi S, Yusuf S. Colchicine in acute myocardial infarction. *New Engl J Med*. 2025; 392(7): 633-42. Article. IF: 84.5; D1

- Jolly SS, d'Entremont MA, Pitt B, Lee SF, Mian R, Tyrwhitt J, Kedev S, Montalescot G, Cornel JH, Stankovic G, Moreno R, Storey RF, Henry TD, Mehta SR, Bossard M, Kala P, Bhindi R, Zafirovska B, Devereaux PJ, Eikelboom J, Cairns JA, Natarajan MK, Schwalm JD, Sharma SK, Tarhuni W, Conen D, Tawadros S, Lavi S, Asani V, Topic D, Cantor WJ, Bertrand OF, Pourdjabbar A, Yusuf S. Routine spironolactone in acute myocardial infarction. *New Engl J Med*. 2025; 392(7): 643-52. Article. IF: 84.5; D1

- Jurado-Román A, Gómez-Menchero A, Rivero-Santana B, Amat-Santos IJ, Jiménez-Valero S, Caballero-Borrego J, Ojeda S, Miñana G, González-García A, Tébar-Márquez D, Camacho-Freire S, Ocaranza-Sánchez R, Domínguez A, Galeote G, Moreno R. Rotational atherectomy, lithotripsy, or laser for calcified coronary stenosis the Roller Coaster-EPIC22 Trial. *JACC-Cardiovasc Inte*. 2025; 18(5): 606-18. Article. IF: 12.7; D1

- Jurado-Román A, González-García A, Jiménez-Valero S, Galeote G, Moreno R. REPLY: Intrastent techniques in the Roller-Ccoastr-EPIC22 trial a missing piece of the puzzle? *JACC-Cardiovasc Inte*. 2025; 18(14): 1830. Letter. IF: 12.7; D1

- Jurado-Román A, Tébar-Márquez D, Basile M, Rivero-Santana B, Zubiaur J, Moreno R. REPLY: Optimizing debulking strategies for heavily calcified coronary lesions. *JACC-Cardiovasc Inte*. 2025; 18(16): 2074-5. Letter. IF: 12.7; D1

- Keramida K, López-Fernández T, Anker MS, Petrie MC, Ameri P, Anderson LJ, Bergler-Klein J, Deswal A, Farmakis D, Ibañez B, Lam CSP, Lang NN, Lyon AR, Mirabel M, Moura B, Paulus WJ, Rakisheva A, Savarese G, Senni M, Tocchetti CG, Metra M, Filippatos G. Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology. *Eur J Heart Fail*. 2025; 27(11): 2152-67. Article. IF: 10.3; D1

- Kotecha D, Bunting KV, Mehta S, Sommer P, Sterlinski M, Rajappan K, Mont L, Guasch E, Boveda S, Boriani G, Sun YZ, van Deutekom C, Gale CP, De Potter TJR, van Gelder IC, Allali Y. Education of healthcare professionals to improve guideline adherence in atrial fibrillation: the STEER-AF cluster-randomized clinical trial. *Nat Med*. 2025; 31(8): 2647-54. Article. IF: 52.5; D1

- Kowalewski M, Dabrowski EJ, Kurasz A, Swieczkowski M, Raffa GM, Kawczynski M, Aerts L, Kuzma L, Wanha W, Batko J, Litwinowicz R, Urbanowicz T, Stec S, Lorusso R, Hanke T, Maesen B, Meani P, Ronco D, Pilato M, Musumeci F, McCarthy P, Cox JL, Pannone L, Merino JL, Pürerfellner H, Badhwar V, La Meir M, de Asmundis C, Lip GH, Suwalski P. Surgical ablation of atrial fibrillation with concomitant cardiac surgery: a state-of-the-art review. *Eur J Cardio-Thorac*. 2025; 67(7): eza187. Review. IF: 3.3; Q1

- Lara-García A, Jurado-Román A, Márquez DT, García AG, Valero SJ, Moreno R. Percutaneous mechanical thrombectomy in subacute pulmonary embolism. *Rev Esp Cardiol (Engl Ed)*. 2025; 78(9): 825-8. Letter. IF: 4.2; Q2

- López-Fernández T, Ameri P. Glucagon-like peptide 1 agonists in cardio-oncology: is it time for a specific focus? *Eur J Prev Cardiol*. 2025; zwaf064. Editorial Material. IF: 10.0; D1

- López-Fernández T, van der Meer P, Lyon AR. An update on the European Society of Cardiology Council of Cardio-Oncology. *Eur Heart J*. 2025; 46(16): 1466-8. Article. IF: 45.3; D1

- Maron DJ, Newman JD, Anthopoulos R, Lu Y, Stevens S, Boden WE, Mavromatis K, Linefsky J, Nair RG, Bockeria O, Gosselin G, Perna GP, Demchenko E, Foo D, Shapiro MD, Champagne MA, Ballantyne C, McCullough P, López-Sendon JL, Rockhold F, Harrell F, Rosenberg Y, Stone GW, Bangalore S, Reynolds HR, Spertus JA, Hochman JS. Guideline-directed medical therapy and outcomes in the ISCHEMIA Trial. *J Am Coll Cardiol*. 2025; 85(12): 1317-31. Article. IF: 22.3; D1

- Márquez DT, Jiménez-Valero S, Jurado-Román A, Galeote G, Meras-Colunga P, Aroca A, Leyra F, Higuera I, Cantador JR, Moreno R. Life-saving combination of extracorporeal membrane

oxygenation, percutaneous aspiration, and valvuloplasty in a pulmonary prosthetic valve endocarditis. *Can J Cardiol*. 2025; 41(4): 761-3. Editorial Material. IF: 5.7; Q1

- Mcgrath BP, Pinilla-Echeverri N, Wood DA, Bainey KR, Sheth T, Schampaert E, Tanguay JF, Dzavik V, Storey RF, Mehran R, Bossard M, Moreno R, Campo G, Rao SV, Cantor WJ, Lavi S, Johnston PV, Guiducci V, Kim HH, Mani T, Nguyen H, Cairns JA, Mehta SR. Left Anterior Descending Nonculprit Lesions and Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. *JACC-Cardiovasc Inte*. 2025; 18(3): 297-307. Article. IF: 12.7; D1

- Meras P, Cobarro L, Merino C, Ruiz-Cantador J, Jiménez S, Balbaci E, Abelleira C, Moreno R. Prevalence and prognostic value of malnutrition in adults with Fontan circulation: retrospective cohort study. *Cardiol Young*. 2025; 35(4): 836-41. Article. IF: 0.8; Q4

- Merino JL, Rossa MV. Contemporary use of antiarrhythmic drugs: practical messages for clinical cardiologists from the EHRA compendium. *Rev Fed Arg Cardiol*. 2025; 54(4): 203-11. Review. IF: 0.4; Q4

- Merino JL, Rossa MV. Contemporary use of antiarrhythmic drugs: practical messages for clinical cardiologists from the EHRA compendium. *Rev Fed Arg Cardiol*. 2025; 54(4): 224-232. Article. IF: 0.4; Q4

- Merino JL, Tamargo J, Blomström-Lundqvist C, Boriani G, Crijns HJGM, Dobrev D, Goette A, Hohnloser SH, Naccarelli G, Reiffel JA, Tfelt-Hansen J, Martínez-Cossiani M, Camm AJ. Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology. *Europace*. 2025; 27(8): euaf076. Article. IF: 10.2; D1

- Merino JL. Aiming for the STARS: radiotherapy for ventricular tachycardia-bright future or cosmic gamble? *Europace*. 2025; 27(1): euae306. Editorial Material. IF: 10.2; D1

- Miserachs M, Martinez-Bueno C, Castro A, Pallarés-Carratalá V, Pijuan-Domenech A, Gordon B, Farràs A, Del Barco E, Higuera T, Carreras E, Goya M. Adverse pregnancy outcomes and cardiovascular disease: a Spanish Cohort

Healthcare (Basel). 2025; 13(7): 728. Article. IF: 3.4; Q1

- Moreno FJA, García JE, Simarro FL, Gutiérrez LA, Peña CM, Vilches AM, Belinchón MR, Hidalgo PP, Cervantes CE. Optimization of adherence to fixed-dose combination therapy in the treatment of cardiovascular risk factors in primary care. *SEMERGEN*. 2025; 51(1): 102337. Article. IF: 1.0; Q4

- Moreno R, Dzavik V, Cairns J, Balasubramanian K, Martínez R, Cantor WJ, Kedev S, Stankovic G, Bertrand O, Pinilla N, Sibbald M, Akl E, Jolly SS. Stent thrombosis in the setting of ST-segment elevation acute myocardial infarction in the contemporary practice: results from the TOTAL randomized trial. *Coronary Artery Dis*. 2025; 36(2): 126-38. Article. IF: 2.2; Q3

- Moreno R, Souza J, Smolnik R, Nombela-Franco L, Van Mieghem NM, Hengstenberg C, Valgimigli M, Jin JM, Ohlmann P, Dangas G, Unverdorben M, Möllmann H. Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial. *Clin Res Cardiol*. 2025; 114(3): 313-22. Article. IF: 3.4; Q2

- Moreno R. In asymptomatic severe AS, early surgery vs. conservative therapy reduced a composite of death, MI, stroke, or HF hospitalization at 63 mo. *Ann Intern Med*. 2025; 178(1): JC6. Editorial Material. IF: 17.2; D1

- Morrone D, Stefanini G, De Carlo M, Giannini C, Toth G, Prunea D, Zivelonghi C, Benedetti A, De Bruyne B, Wilgenhof A, Kanovsky J, Kala P, Holmvang L, Hasbak M, Hildick-Smith D, Cockburn J, Amabile N, Veugeois A, Hovasse T, Neylon A, Honton B, Farah B, Gori T, Knorr M, Wolf A, Schmit T, Hausleiter J, Stark KK, Abdel-Waha M, Feistritz HJ, Woitek F, Linke A, Leick J, Afzal S, Alexopoulos D, Varlamos C, Tsioufis K, Dimitriadis K, Testa L, Squillace M, Conrotto F, D'Ascenzo F, Campo G, Cocco M, Di Mario C, Caniato F, Ribichini FL, Prati D, Tarantini G, Cardaioli F, Burzotta F, Paraggio L, Bedogni F, Arzuffi L, Chieffo A, Ghizoni G, Davidavicius G, Budrys P, Van Mieghem N, Daemen J, Brinkmann R, Bante H, Lesiak M, Iwanczyk S, Pregowski J, Skowronski J,



3.2. Cardiovascular Area

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Madeira S, Raposo L, Estevez-Loureiro R, Sisinni A, Escaned J, Jeronimo A, Moreno R, Jiménez-Valero S, Vriesendorp P, Pustjens T, Van Geuns R, Damman P, Van de Hoef T, Van der Harst P, Mamas MA, Duckett S, Mikhail G, Lucarelli C, Berry C, De Caterina R. Myocardial infarction with nonobstructive coronary arteries - the European PERspective (SNIPER) survey. *J Cardiovasc Med*. 2025; 26(12): 731-40. Article. IF: 2.6; Q2

- Muñoz LC, Sánchez-Somonte P, Castrejón-Castrejón S, Martínez-Cossiani M, Al Razzo O, Merino JL. When leads are not an option: Optimizing subcutaneous implantable cardioverter-defibrillator and leadless pacemaker interaction. *Hearhythm Case Rep*. 2025; 11(11): 1236-9. Article. Not Indexed

- Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Miller D, Nauck MA, Nishiyama H, Nissen SE, Sattar N, Weerakkody G, Wiese RJ, Zinman B, Zoungas S, Basile J, Davies MJ, Giorgino F, Kellerer M, Ji LN, Varkonyi T, Menon V, Broder JC, Herschtal A, D'Alessio D, (Castro Conde A). Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. *New Engl J Med*. 2025; 393(24): 2409-20. Article. IF: 84.5; D1

- Nuhe J, Ponz I, Sánchez VS, Bóveda J, Gaitán A, López-Linares K, García-Cosío MD, Cebada FS, González JS, Ynsaurriaga FA, Ruiz-Cabello J, Ibáñez B, Delgado JF. Four-Dimensional magnetic resonance pulmonary flow imaging for assessing pulmonary vasculopathy in patients with postcapillary pulmonary hypertension. *J Clin Med*. 2025; 14(3): -929. Article. IF: 3.3; Q1

- Önder R, Desteghe L, Vijgen J, Collins R, Dabrowski R, Farkowski MM, Figueiredo MJD, Hereijgers MJM, Hofer D, Lau CP, Lee G, Linz D, Lobeek M, López T, McAuliffe C, Merino JL, Potpara T, Sanders P, Shamloo AS, Sterlinski M, Svennberg E, van Deutekom C, Van Gelder I, Rienstra M, Heidebuchel H. Development of three-step holistic care pathways to detect and manage comorbidities in patients with atrial fibrillation: the Horizon 2020 EHRA-PATHS consortium. *Eur Heart J Open*. 2025; 5(5): e0af120. Article. IF: 4.3; Q2

- Ortiz MR, Arbelo E, Rabadan IR, Marín F, Cabeza AP, Rivas RM, Peinado RP, Alberca AV, Criado AI,

Muñoz AV, Asensi JO, Lechuga AD, Somoza FJE, Sánchez MA. The European Society of Cardiology quality indicators in atrial fibrillation in centers of excellence in Spain: the SEC-EXCELENTE FA registry. *Rev Esp Cardiol (Engl Ed)*. 2025; 78(5): 389-400. Article. IF: 4.2; Q2

- Pallarés-Carratalá V, Ruiz-García A, Fragoso AS, Escobar-Cervantes C, Cervera-Pérez MI, Alonso-Moreno EJ, Arranz-Martínez E, Barquilla-García A, Rey-Aldana D, Polo-García J, Cinza-Sanjurjo S. Improvement of cardiometabolic control with dapagliflozin in patients with type 2 diabetes in primary care: The AGORA-AP Study. *Med Lith*. 2025; 61(12): 2087. Article. IF: 2.9; Q1

- Parés-Guillén E, Yuste L, Rojo F, Moreno R. The ISPPu9 insertion sequence of *Pseudomonas putida* KT2440 generates various circular intermediates enabling modular transposition. *Nucleic Acids Res*. 2025; 53(14): gkaf668. Article. IF: 15.0; D1

- Pérez-Blanco A, González-Vilchez F, González-Costello J, Royo-Villanova M, Miñambres E, Cuenca JJ, Cánovas SJ, Garrido IP, Moreno-González G, Sbraga F, García-Quintana A, Peña VJ, Portela FA, Almenar-Bonet L, Martínez-León J, Tur A, Ruiz-Arranz A, Caravaca-Pérez P, Sandoval E, Gómez-Bueno M, Pérez-Redondo M, Villar S, Cobo M, Nistal JF, Adsuar-Gómez A, Peinado AA, Blázquez-Bermejo Z, Coll E, Crespo-Leiro MG, Cuerpo G, de la Calle B, Estébanez B, Fernández-García ME, Mosteiro F, Ponz I, Sánchez-Rivas J, Sánchez-Vicario F, Sobrino JM, Domínguez-Gil B. DCDD heart transplantation with thoraco-abdominal normothermic regional perfusion and static cold storage: the experience in Spain. *Am J Transplant*. 2025; 25(7): 1526-39. Article. IF: 8.1; D1

- Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, Ma CS, Goodman SG, Oldgren J, Hammett C, Lopes RD, Akao M, De Caterina R, Kirchhof P, Gørg DA, Hemels M, Rienstra M, Jones WS, Harrington J, Lip GYH, Ellis SJ, Rockhold FW, Neumann C, Alexander JH, Viethen T, Hung J, Coppolecchia R, Mundl H, Caso V, (Merino Llorens JL). Asundexian versus Apixaban in Patients with Atrial Fibrillation. *New Engl J Med*. 2025; 392(1): 23-32. Article. IF: 84.5; D1

- Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M, Marsan NA, Barili F, Bonaros N, Cosyns B, De Paulis R, Gamra H, Jahangiri M, Jeppsson A, Klautz RJM, Mores B, Pérez-David E, Pöss J, Prendergast BD, Rocca B, Rossello X, Suzuki M, Thiele H, Tribouilloy CM, Wojakowski W. 2025 ESC/EACTS Guidelines for the management of valvular heart disease Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2025; 46(44): 4635-6. Review. IF: 45.3; D1

- Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M, Marsan NA, Barili F, Bonaros N, Cosyns B, De Paulis R, Gamra H, Jahangiri M, Jeppsson A, Klautz RJM, Mores B, Pérez-David E, Pöss J, Prendergast BD, Rocca B, Rossello X, Suzuki M, Thiele H, Tribouilloy CM, Wojakowski W. 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur J Cardio-Thorac*. 2025; 67(8): eza276. Article. IF: 3.3; Q1

- Rao VU, Deswal A, Lenihan D, Dent S, López-Fernández T, Lyon AR, Barac A, Palaskas N, Chen MH, Villarraga HR, Sadler D, Campbell CM, Skurka K, Wagner MJ, Totzeck M, Ruddy KJ, Heidenreich P, Thomas R, Addison D, Ganatra S, Cheng RC, Reeves D, Ghosh AK, Herrmann J. Quality-of-care measures for cardio-oncology an IC-OS and ACC cardio-oncology leadership council perspective. *Jacc Cardiooncol*. 2025; 7(3): 191-202. Article. IF: 15.5; D1

- Redondo EA, Rodríguez SOR, Rodrigo CU, Codón JC, Roman AJ, Moreno R. Percutaneous decannulation of peripheral veno-arterial extracorporeal membrane oxygenation using the Manta closure device. *REC-Interv Cardiol*. 2025; 7(3): 187-9. Letter. IF: 1.5; Q3

- Rienstra M, Woite-Silva AC, Kuijper A, Eijlsbouts S, Kraaier K, Janota T, Van Ofwegen C, Tuininga Y, Badings E, Merino JL, Ruskin JN, Camm AJ, Kowey PR, Dufton C, Maupas J, Parsell D, Belardinelli L. Flecainide acetate inhalation

solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial. *Europace*. 2025; 27(4): euaf064. Article. IF: 10.2; D1

- Rivero-Santana B, Balbacid-Domingo E, Abelleira-Pardeiro C, de Lera CL, del Val VA, Jiménez-Valero S, Fernández-Velasco M, Moreno R, Gutiérrez-Laraya F. Microcirculatory dysfunction and its role in diagnosing acute rejection in pediatric heart transplantation: a pilot study. *Diagnostics (Basel)*. 2025; 15(5): 545. Article. IF: 3.8; Q1

- Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Monzonis AM, Zatarain E, Alvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodríguez I, Soto AB, Cadenas R, Ozores PP, Ramírez SP, Salvador MM, Valbuena S, Gasso LF, Juárez V, Severo A, Terol B, Alvarez TD, Rodríguez O, Brion M, González-Costello J, Albendea MC, González-Juanatey JR, Moreno R, López-Sendón J, López-Fernández T. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. *Eur Heart J*. 2025; 46(3): 273-84. Article. IF: 45.3; D1

- Rivero-Santana B, Saldaña-García J, Jurado-Román A, Cantolla-Pablo P, Gil-Fernández M, López-Sendón J, Tardif JC, Moreno R, Fernández-Velasco M. Early anti-inflammatory therapy in acute myocardial infarction: A network meta-analysis of timing-dependent effects in 23 randomized trials and 28,220 patients. *Atherosclerosis*. 2025; 408: 120443. Article. IF: 7.1; D1

- Ruiz-García A, Arranz-Martínez E, Serrano-Cumplido A, Cinza-Sanjurjo S, Escobar-Cervantes C, Polo-García J, Pallarés-Carratalá V. From Metabolic Syndrome to Cardio-Kidney-Metabolic Syndrome in the SIMETAP Study: Prevalence rates of metabolic syndrome and its independent associations with cardio-renal-metabolic disorders other than its defining criteria. *Biomedicines*. 2025; 13(3): 590. Article. IF: 4.5; Q2

- Ruiz-García A, Pallarés-Carratalá V, Serrano-Cumplido A, Pascual-Fuster V, Arranz-Martínez E, Escobar-Cervantes C. From the cardiovascular-kidney-metabolic disorders to the atherosclerotic cardiovascular diseases: their prevalence rates and



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

independent associations in the SIMETAP Study. *J Clin Med*. 2025; 14(11): 3940. Article. IF: 3.3; Q1

- **Saksena S, Slee A, Merino JL, Goette A, Boriani G, Kowey PR, Piccini JP, Reiffel JA, Blomström-Lundqvist C, Camm AJ.** An international physician survey of current ablation practices in atrial fibrillation: An AIM-AF substudy. *Heart Rhythm*. 2025; 22(9): 2174-82. Article. IF: 7.0; Q1
- **Sales JC, Cervantes CE, Gómez-Barrado JJ, Cayuelas JMA, del Egido AG, Martín JJC, Rodrigo AIH, Corbi-Pascual M, Cancelo AV, Vidal-Pérez R, Fernández-Friera L, Olmeda ES, Aguilera-Saborido A, Romero AF, Hidalgo AS, Pérez-Sádaba F, Freixa-Pamias R.** Impact of therapeutic inertia in lipid-lowering therapy in patients at very high cardiovascular risk. *Clin Investig Arterioscler*. 2025; 37(6): 500773. Article. IF: 1.9; Q3
- **Salinas GLA, León AM, Cano DA, Esteban-Fernández A, Flórez JMV, Díaz SD, Górriz-Magaña J, Delgado GD, González-Manzanares R, Caravaca-Pérez P, Pastor-Pérez FJ, Valdivieso-Moré S, Quiles J, Ponz I, Escolar V, Lincango EOB, Báez-Ferrer N, Gallego G, Almenar L, de la Varga IG, Codina P, Mayoral AR, Fort A, Lozano MJP, González-Calle D, Gómez-Otero I, Mosteiro CS, Cobo M, Piqueras-Flores J, Bonanad C, Huerta A, Vallverdú MF, Díez-Villanueva P.** Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry. *Esc Heart Fail*. 2025; 12(4): 3163-72. Article. IF: 3.8; Q2
- **Salinas P, Álvarez ABC, Pérez PJ, Vázquez-Álvarez ME, Jurado-Román A, Juárez M, Corbi-Pascual M, Martín MV, Jiménez-Mazuecos J, Rodríguez SOR, Quevedo VR, Lázaro M, Viana-Tejedor A, Moreiras JM, Martín-Asenjoi R.** Catheter-directed interventions in acute pulmonary embolism. Position statement of SEC-Interventional Cardiology Association/SEC-Ischemic Heart Disease and Acute Cardiovascular Care Association/SEC-Working Group on Pulmonary Hypertension. *Rev Esp Cardiol (Engl Ed)*. 2025; 78(3): 239-51. Article. IF: 4.2; Q2
- **Sambola A, Campuzano R, Castro A, Goya M, Coronado P, Fernández-Olmo R, María-Tablado MA, Ortiz-Cortés C, Ortolá X, Pallarés-**

- Carratala V, Pijuan-Domenech A, Plata RM, Sánchez-Hernández RM, Siurana JM, Timoteo C, Viejo-Hernández B.** Primary and secondary cardiovascular prevention through life cycles in women. Consensus document of the SEC-GT CVD in Women, ACP-SEC, SEGO, AEEM, SEEN, semFYC, SEMERGEN, AEP, and AEM. *Rev Esp Cardiol (Engl Ed)*. 2025; 78(7): 639-51. Article. IF: 4.2; Q2
- **Samuel M, Berry C, Dubé MP, Koenig W, López-Sendón J, Maggioni AP, Pinto FJ, Roubille F, Tardif JC.** Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. *Eur Heart J*. 2025; 46(26): 2552-63. Article. IF: 45.3; D1
- **Sánchez-Recalde A, Domínguez-Rodríguez LM, Rosseel L, Nombela-Franco L, Pfister R, Amat-Santos I, Butter C, Di Mauro M, Cruz-González I, Freixa X, Swaans M, Wilde C, Cacula D, Sarnago F, del Trigo M, Estévez-Loureiro R, López-Mínguez JR, De Torres F, Montenegro M, Pérez-Fernández R, Guzmán G, Pajín F, Mylotte D, Pan MN, Kristoff C, Carrillo-Suárez X, Torre JMD, Quevedo VR, Salido L, Parraga R, Althoff J, Fernández-Cordón C, Guarracini S, López-Tejero S, Altisent OAJ, Lautenschläger L, Ramos R, Puri R, Zamorano JL.** Bicaval TricValve implantation in patients with severe tricuspid regurgitation 1-year outcomes from the TricBicaval Registry. *JACC-Cardiovasc Inte*. 2025; 18(15): 1913-24. Article. IF: 12.7; D1
- **Santamaría R, Escobar C, Aranda U, Palacios B, Capel M, Hernández I, Cebrián A, Alcázar R, Gorostidi M.** Cardiovascular and renal outcomes according to KDIGO stages of chronic kidney disease in the Spanish population: Insights from real-world evidence. *Nefrología*. 2025; 45(8): 501340. Article. IF: 2.1; Q3
- **Santamaría R, Escobar C, Aranda U, Palacios B, Capel M, Hernández I, Cebrián A, Alcázar R, Gorostidi M.** Magnitude of chronic kidney disease in Spain. *Nefrología (Engl Ed)*. 2025; 45(5): 415-7. Letter. Not Indexed
- **Sarti A, Erríquez A, Dal Passo B, Casella G, Guiducci V, Moreno R, Escaned J, Marchini F, Cocco M, Verardi FM, Clò S, Cagliani S, Farina J, Barbato E, Vadalà G, Cavazza C, Capecci A, Gallo F, Campo G, Biscaglia S.**

Complete revascularization in older patients with myocardial infarction with or without complex nonculprit lesions. *Circ-Cardiovasc Inte*. 2025; 18(11): e015902. Article. IF: 7.2; Q1

- **Skouri H, Girerd N, Monzo L, Petrie MC, Boehm M, Adamo M, Mullens W, Savarese G, Yilmaz MB, Amir O, Bayes-Genis A, Bozkurt B, Butler J, Chioncel O, Mebazaa A, Merino JL, Moura B, Ponikowski P, Seferovic P, Rosano GMC, Metra M.** Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2025; 27(4): 707-22. Article. IF: 10.3; D1
- **Slater J, Maron DJ, Jones PG, Bangalore S, Reynolds HR, Fu ZX, Stone GW, Kirby R, Hochman JS, Spertus JA, ISCHEMIA Res Grp (López-Sendon JL, Castro Conde A, Refoyo Salicio E, Guzman G, Galeote G, Valbuena S).** Evaluating the appropriate use criteria for coronary revascularization in stable ischemic heart disease using randomized data from the ISCHEMIA Trial. *Circ-Cardiovasc Qual*. 2025; 18(3): e010849. Article. IF: 6.9; Q1
- **Svennberg E, Merino JL, Andrade J, Anselmino M, Arbelo E, Boersma E, Boriani G, Breithardt G, Chung MN, Chyou J, Cohen A, Nielsen JC, Dichtl W, Diederichsen SZ, Dobrev D, Doehner W, Dworatzek E, Fabritz L, Filgueiras-Rama D, Gimpelewicz C, Hack G, Hatem S, Healey J, Heidebuchel H, Hijazi Z, Holst AG, Hove-Madsen L, Jalife J, van Leerdam R, Linz D, Lip GYH, Lubitz S, de Melis M, Meyer R, Orszkowski M, Parwani AS, Porta-Sánchez A, de Potter T, Ravens U, Rienstra M, Rillig A, Rivard L, Scherr D, Schnabel RB, Schotten U, Simovic S, Sinner M, Sohns C, Sommer P, Steinbeck G, Steven D, Sultan A, Thomalla G, Toennis T, Tzeis S, Voigt N, Wadhwa M, Wakili R, Witt H, Goette A, Kirchhof P.** Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference. *Europace*. 2025; 27(12): eua318. Article. IF: 10.2; D1
- **Tamburrini G, García CD, López-Fernández T.** Advances in cardioprotection strategies: focusing

on breast cancer and beyond through novel biomarkers and pharmacological approaches. *Eur Cardiol*. 2025; 20: 23. Review. IF: 4.6; Q1

- **Tébar D, Jurado-Román A, Jiménez-Valero S, Galeote G, González A, Rivero B, García A, Elizalde JMA, Lorenzo A, Capitán CF, Torres R, Soto C, Alcolea S, Rosillo S, Codón JC, Arbas E, Tejera F, Plaza I, Boscal L, Moreno R.** Percutaneous pulmonary thrombectomy with aspiration catheters in patients with high-risk pulmonary embolism and absolute contraindication to systemic thrombolysis. *Cardiovasc Revasc Med*. 2025; 70: 56-61. Article. IF: 2.3; Q3
- **Tébar-Márquez D, Díez-Vidal A, Tung-Chen Y.** Antithrombotic therapy after percutaneous left atrial appendage closure: should it be the same for everyone? *Rev Esp Cardiol (Engl Ed)*. 2025; 78(8): 679-81. Editorial Material. IF: 4.2; Q2
- **Tilz RR, Popescu SS, Pürerfellner H, Kuck KH, Xiang K, Uzunoglu EC, Heeger CH, Vogler J, Tandri H, Assis F, Shantha G, Merino JL, Catanzaro JN.** Impact of ablation energy on mortality after oesophageal fistula and injury complicating atrial fibrillation ablation procedures: results from a worldwide FDA database, the POTTER-AF 2 study. *Eur Heart J Open*. 2025; 5(6): eaf146. Article. IF: 4.3; Q2
- **Tilz RR, Pürerfellner H, Kuck KH, Merino JL, Schmidt V, Vogler J, Xiang K, Uzunoglu EC, Heeger CH, Tandri H, Assis F, Steven D, Veltmann C, Catanzaro JN, Popescu SS.** Underreporting of complications following AF ablation: Comparison of the manufacturer and user facility device experience FDA database and a voluntary invitation-based registry: The POTTER-AF 3 study. *Heart Rhythm*. 2025; 22(6): 1472-9. Article. IF: 7.0; Q1
- **Tiong D, Pinilla-Echeverri N, Wood DA, Mehran R, Storey RF, Feldman L, Moreno R, Rao S, Cantor WJ, Welsh R, Bainey KR, Cohen EA, Tsang MB, Sibbald M, Natarajan MK, Wijesena D, Mani T, Nguyen H, Cairns JA, Mehta SR.** Impact of complete revascularisation in relation to left ventricular function in patients with ST-segment elevation myocardial infarction and multivessel disease: a post hoc analysis of the COMPLETE randomised trial. *Eurointervention*. 2025; 21(20): e1198-208. Article. IF: 9.2; D1



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

- **Torremocha A, Tébar D, Jurado A.** The role of non-invasive tests in pulmonary embolism. *Interv Cardiol.* 2025; 20: e26. Article. IF: 2.0; Q3
- **Traykov V, Puerefellner H, Burri H, Foldesi CL, Scherr D, Duncker D, Arbelo E, Botto GL, Boriani G, Heidebuchel H, Malaczynska-Rajpold K, Farkowski MM, Dagres N, Szymanski P, Huculeci R, Casado-Arroyo R, Boveda S, Merino JL.** EHRA perspective on the digital data revolution in arrhythmia management: insights from the association's annual summit. *Eurpace.* 2025; 27(8): euaf149. Article. IF: 10.2; D1
- **van der Waerden RGA, Volleberg RHJA, Luttikholt TJ, Cancian P, van der Zande JL, Stone GW, Holm NR, Kedhi E, Escaned J, Pellegrini D, Guagliumi G, Mehta SR, Pinilla-Echeverri N, Moreno R, Räber L, Roleder T, van Ginneken B, Sánchez C, Isgum I, van Royen N, Thannhauser J.** Artificial intelligence for the analysis of intracoronary optical coherence tomography images: a systematic review. *Eur Heart J Digit Health.* 2025; 6(2): 270-84. Review. IF: 5.3; Q1
- **Vázquez-Sánchez S, Blasco A, Fernández-Corredoira P, Cantolla P, Mercado-García E, Rodríguez-Sánchez E, González-Lafuente L, Poveda J, González-Moreno D, Matutano A, Peribañez S, García-Consuegra I, Volpe M, Fernández-Velasco M, Ruilope LM, Ruiz-Hurtado G.** Recombinant Klotho administration after myocardial infarction reduces ischaemic injury and arrhythmias by blocking intracellular calcium mishandling and CaMKII activation. *J Pathol.* 2025; 265(3): 342-56. Article. IF: 5.4; Q1
- **Vila-García J, Hernández GD, Manjavacas AMI, López SCV, García GG, Moriche EP, Moreno R.** A Torn leaflet an unusual complication of a degenerated transcatheter aortic valve prosthesis. *JACC-Cardiovasc Inte.* 2025; 18(8): 1062-4. Editorial Material. IF: 12.7; D1
- **Viñas-Mendieta AE, Gallardo-Grajeda A, López-Fernández T.** Cardio-oncology: chances and challenges. *Basic Res Cardiol.* 2025; 120(1): 3-9. Review. IF: 9.2; D1
- **White HD, O'Brien SM, Boden WE, Fremes SE, Bangalore S, Reynolds HR, Stone GW, Ali ZA, Parakh N, López-Sendón JL, Wang YX, Chen YQ, Mark DB, Chaitman BR, Spertus JA, Maron DJ,**

- Hochman JS, ISCHEMIA Res Grp.** Use of coronary artery bypass graft surgery and percutaneous coronary intervention and associated outcomes in the ISCHEMIA trial. *Am Heart J.* 2025; 289: 78-94. Article. IF: 3.4; Q2
- **Wilkinson C, Bhatta A, Batra G, Aktaa S, Smith AB, Dwight J, Rucinski M, Chappell S, Alfredsson J, Erlinge D, Ferreira J, Guomundsdóttir LJ, Hrafnkelsdóttir TJ, Ingimarsdóttir LJ, Irs A, Jánosi A, Jarai Z, Oliveira-Santos M, Popescu BA, Vasko P, Vinereanu D, Yap J, Bugiardi R, Cenko E, Nadarajah R, Sydes MR, James S, Maggioni AP, Wallentin L, Casadei B, Gale CP, Global Cardiovasc Outcomes Consortium, ACNAP, ACVC, EACVI, EAPC, EAPCI, EHRA, ESC Comm Young CV Professionals, ESC Registry Comm, HFA, ESC Patient Forum These Working Grp (Merino Llorens JL).** Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). *Eur Heart J.* 2025; 46(2): 190-214. Article. IF: 45.3; D1
- **Zamorano JL, Vörös G, Calvi V, Osca J, Quesada A, Vernooy K, Martínez JG, Maass AH, Nof E, Tolosana JM, Pardo M, Barr C, Fernández I, Merino JL, Ellery S, Ricoy-Martínez E, Belotti G, Seidlmayer L, García S, Tönnis T, Campbell NG, Foley P, Brockmeier J, Nürnberg M, Ruiz-Granell R, Prinzen FW, Lorente-Ros A, Moreno A, Pinart M, Ver Heyen M, Van Erven L.** Sex-specific response to cardiac resynchronization therapy: the BIOJ WOMEN trial. *Int J Cardiol.* 2025; 438: 133526. Article. IF: 3.3; Q2
- **Zeppenfeld K, Rademaker R, Al-Ahmad A, Carbucicchio C, De Chillou C, Cvek J, Ebert M, Ho G, Kautzner J, Lambiase P, Merino JL, Lloyd M, Misra S, Pruvot E, Sapp J, Schiappacasse L, Sramko M, Stevenson WG, Zei PC, Wichterle D, Chrispin J, Siklody CH, Neuwirth R, Pelargonio G, Reichlin T, Robinson C, Tondo C.** Patient selection, ventricular tachycardia substrate delineation, and data transfer for stereotactic arrhythmia radioablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society. *Eurpace.* 2025; 27(4): euae214. Article. IF: 10.2; D1

Research projects

- **Alonso Martín JJ.** Inflamación y disfunción endotelial en el infarto agudo de miocardio con arterias coronarias con y sin lesiones significativas (PI24/02079). ISCIII. 2025-2027. **Managment centre: FIBHULP**
- **Fernández Velasco M.** Determinación de nuevos mediadores del sistema inmune innato como biomarcadores de daño cardíaco en el infarto agudo de miocardio. Sociedad Española de Cardiología (SEC). 2019-Ongoing. **Managment centre: FIBHULP**
- **Fernández Velasco M.** New inflammatory targets for atrial myopathy associated with heart failure (PI20/01482). ISCIII. 2021-2025. **Managment centre: FIBHULP**
- **Fernández Velasco M.** Nuevos mecanismos nanomoleculares implicados en la fisiopatología de la insuficiencia cardíaca (CNS2023-145161). MICINN. 2024-2026. **Managment centre: FIBHULP**
- **Fernández Velasco M.** Papel de los receptores nod1 en la cardiotoxicidad inducida por inmunoterapia en pacientes oncológicos (PI23/01014). ISCIII. 2024-2026. **Managment centre: FIBHULP**
- **Jurado Román A.** ASSIST_AI scalable solution for st myocardial infarction (2023391). EIT-HEALTH. 2023-2025. **Managment centre: FIBHULP**
- **López Fernández T.** Creación de la base de datos etiquetada más grande del mundo para potenciar el análisis de ECG impulsado por ia para el diagnóstico temprano y predictivo de enfermedades cardiovasculares (CPP2024-011665). MICINN. 2025-2028. **Managment centre: FIBHULP**
- **López Fernández T.** The Legacy of Anthracycline Imprints in Bone Marrow: Uncovering Long-Term Cardiovascular Risks in Cancer Survivors" (TERESA LOPEZ-CNIC CAIXA CNIO). FUNDACION CENTRO NACIONAL INVESTIGACIONES CARDIOVASCULARES. 2025-2028. **Managment centre: FIBHULP**
- **López-Sendón Hentschel JL.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_GRUPO II). ISCIII. 2024-2027. **Managment centre: FIBHULP**

- **Merino Llorens JL.** Ablación mediante aislamiento de venas pulmonares solo o combinado con ablación lineal para eliminar recurrencias de fa persistente: un ensayo clínico multicéntrico aleatorizado (SUPAFER) (PI22/00278). ISCIII. 2023-2027. **Managment centre: FIBHULP**
- **Merino Llorens JL.** Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centred care pathways (EHRA-PATHS_JOSE LUIS MERINO). UE. 2021-2026. **Managment centre: FIBHULP**
- **Merino Llorens JL.** Aplicaciones de radiofrecuencia de alta potencia para ablación de venas pulmonares más rápida y segura (5064 POWERFAST III). FIBHULP. 2019-Ongoing. **Managment centre: FIBHULP**
- **Merino Llorens JL.** European Research Institute on Simulation (HORIZON-WIDERA-2024-ERA-02-01). EU. 2025-2028. **Managment centre: HULP**
- **Merino Llorens JL.** Impacto del aislamiento de venas pulmonares combinado con líneas de ablación en pacientes con insuficiencia tricuspídea severa y fibrilación auricular persistente sin indicación convencional de ablación (TRIABLA-AF) (SECARIT-INVIMUL 25/04). Sociedad Española de Cardiología (SEC). 2025-2026. **Managment centre: HULP**
- **Merino Llorens JL.** Implementation of personalised risk prediction and prevention of sudden cardiac death after myocardial infarction (PROFID EHRA) (GA 847999). EU. 2023-2026. **Managment centre: FIBHULP**
- **Moreno Gómez JR.** Bridging gaps in caRdiAC health managEment (GRACE_MORENO). UE. 2025-2029. **Managment centre: FIBHULP**
- **Moreno Gómez JR.** Leading Innovation in Cardiovascular Pathways for Improved Patient Outcomes (EUROHEARTPATH_MORENO). UE. 2025-2030. **Managment centre: FIBHULP**
- **Pérez David E.** Caracterización de la fibrosis miocárdica en transposición de grandes vasos y ventrículo derecho sistémico mediante técnicas de imagen y biomarcadores moleculares y asociación con eventos adversos (PI22/00707). ISCIII. 2023-2027. **Managment centre: FIBHULP**
- **Pérez David E.** Medical augmented reality and digital twins (TEC-2024/COM-44). CM. 2025-2028.



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Managment centre: FIBHULP

- **Pérez David E.** Rigorous atrial analysis in advanced interatrial block (ARABIA) (PI21/01501_ CONVENIO). FUNDACION BIOMEDICA HOSPITAL GREGORIO MARAÑON. 2025-2025. Managment centre: FIBHULP

Clinical Trials

- **Antorrena Miranda MI.** Estudio de fase iii, aleatorizado, doble ciego, controlado con placebo y motivado por los acontecimientos para demostrar la eficacia y seguridad de milvexian, un inhibidor oral del factor xia, después de padecer un síndrome coronario agudo reciente.
Type/Phase: III
Sponsored by: Janssen Research & Development, Llc.
Signature date: 01/10/2025
- **Antorrena Miranda MI.** Phase 2, multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of cdr132l on reverse cardiac remodelling in participants with heart failure with preserved ejection fraction and left ventricular hypertrophy.
Type/Phase: II
Sponsored by: Novo Nordisk A/S.
Signature date: 10/12/2025
- **Antorrena Miranda MI.** Phase 2, multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of cdr132l on reverse cardiac remodelling in participants with heart failure with preserved ejection fraction and left ventricular hypertrophy.
Type/Phase: II
Sponsored by: Novo Nordisk A/S.
Signature date: 29/05/2025
- **Antorrena Miranda MI.** Phase 2, multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of cdr132l on reverse cardiac remodelling in participants with heart failure with reduced/mildly reduced ejection fraction and left ventricular hypertrophy.
Type/Phase: II
Sponsored by: Novo Nordisk A/S.
Signature date: 06/05/2025
- **Antorrena Miranda MI.** Phase 2, multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of cdr132l on reverse cardiac remodelling in participants with heart

failure with reduced/mildly reduced ejection fraction and left ventricular hypertrophy.

- **Castro Conde A.** Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (surpass-cvot).
Type/Phase: II
Sponsored by: Novo Nordisk A/S.
Signature date: 10/12/2025
- **Guzmán Martínez G.** Registro multicéntrico español sobre la insuficiencia aórtica moderada y severa.
Type/Phase: No EPA
Sponsored by: Guzmán Martínez, Gabriela.
Signature date: 30/10/2025
- **Galeote García G.** safety and effectiveness of short-term single antiplatelet therapy after left atrial appendage closure with the lambre device in patients with nonvalvular atrial fibrillation: a multinational real-world registry. (s-sapt secure-lambre registry).
Type/Phase: E0m prospectivo
Sponsored by: Fundación Epic.
Signature date: 13/03/2025
- **Iniesta Manjavacas AM.** EASI-HF Reduced – Ensayo de superioridad de fase III, doble ciego, aleatorizado y con grupos paralelos para evaluar la eficacia y la seguridad del uso combinado del vicadrostal (bi 690517) y la empagliflozina por vía oral en comparación con un placebo y la empagliflozina en participantes con insuficiencia cardíaca crónica sintomática (ic: grado ii-iv de la clasificación de la nyha) y una fracción de eyección ventricular izquierda (fevi) <40 %.
Type/Phase: III
Sponsored by: Boehringer Ingelheim International GmbH.
Signature date: 15/09/2025
- **Iniesta Manjavacas AM.** Estrategia de descongestión guiada por reds en pacientes hospitalizados por insuficiencia cardíaca: el estudio Reds-Safe HF II.
Type/Phase: PRODUCTO SANITARIO
Sponsored by: Fundacion Hospital Ramon Y Cajal.
Signature date: 03/07/2025

- **Iniesta Manjavacas AM.** Estudio clínico controlado y abierto para evaluar el biomarcador hsa-rna-chr8:96 en el diagnóstico de miocarditis aguda.
Type/Phase: OTROS
Sponsored by: Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia.
Signature date: 18/02/2025
- **Iniesta Manjavacas AM.** Retrospective observational study to describe real-world treatment patterns and clinical profile of patients with chronic heart failure and reduced ejection fraction treated with vericiguat in routine clinical practice in spain: veripract study.
Type/Phase: EPA-OD
Sponsored by: Bayer Hispania S. L. U.
Signature date: 16/01/2025
- **Iniesta Manjavacas AM.** Triton-CM: estudio global de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de nucsirán en pacientes con amiloidosis por transtiretina con miocardiopatía (amiloidosis attr con miocardiopatía).
Type/Phase: III
Sponsored by: Alnylam Pharmaceuticals Inc.
Signature date: 03/10/2025
- **Jurado Román A.** Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with st-segment elevation myocardial infarction.
Type/Phase: OTROS
Sponsored by: Jurado Román, Alfonso.
Signature date: 22/07/2025
- **Merino Llorens JL.** Anexo 1 6631 marcapasos para la bradicardia con modulación del intervalo av para el tratamiento de la tensión arterial.
Type/Phase: PRODUCTO SANITARIO
Sponsored by: Orchestra Biomed, Inc.
Signature date: 25/03/2025
- **Merino Llorens JL.** Easthigh - Afnet 11 ensayo: ablación temprana de fibrilación auricular para la prevención de accidentes cerebrovasculares en pacientes con alta carga de comorbilidades.
Type/Phase: OTROS
Sponsored by: Kompetenznetz Vorhofflimmern E.V.
Signature date: 18/06/2025
- **Merino Llorens JL.** Marcapasos para la bradicardia con modulación del intervalo av para el tratamiento de la tensión arterial.

Type/Phase: PRODUCTO SANITARIO
Sponsored by: Orchestra Biomed, Inc.
Signature date: 10/09/2025

- **Moreno Gómez JR.** A multicenter, double-blind, randomized, placebo-controlled study of orticumab in participants with prior myocardial infarction who have elevated coronary inflammation based on fat attenuation index (fai) score assessed by coronary computed tomography angiography (ccta).
Type/Phase: IIb
Sponsored by: Abcentra Llc.
Signature date: 20/05/2025
- **Moreno Gómez JR.** A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of an oral branched-chain ketoacid dehydrogenase inhibitor, PF-07328948, in adults with heart failure (branch-hf).
Type/Phase: II
Sponsored by: Pfizer Inc.
Signature date: 09/07/2025
- **Moreno Gómez JR.** A phase 2A, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of JTT-861 administered for 12 weeks in subjects with heart failure with reduced ejection fraction (power-hf).
Type/Phase: IIa
Sponsored by: Akros Pharma Inc.
Signature date: 10/07/2025
- **Moreno Gómez JR.** Anexo randomised, double-blind, placebo-controlled study to investigate a single administration of BI765845 on top of standard of care in patients with acute myocardial infarction.
Type/Phase: II
Sponsored by: Boehringer Ingelheim International GmbH.
Signature date: 21/01/2025
- **Moreno Gómez JR.** Clinical impact of underexpansion criteria of the accurate neo2 valve.
Type/Phase: PRODUCTO SANITARIO
Sponsored by: Fundacion Para La Investigacion Biomedica De Cordoba Fibico.
Signature date: 30/09/2025
- **Moreno Gómez JR.** Efectos de ziltivekimab versus placebo en los resultados cardiovasculares



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



en pacientes con infarto agudo de miocardio y evidencia angiográfica de enfermedad arterial coronaria.

Type/Phase: IIIa

Sponsored by: Novo Nordisk Pharma, S.A.

Signature date: 15/07/2025

- **Moreno Gómez JR.** Ensayo de fase 2, adaptativo, doble ciego, controlado con placebo, aleatorizado y multicéntrico para evaluar la eficacia, seguridad y tolerabilidad de la infusión intracoronaria de ab-1002 en sujetos adultos con insuficiencia cardíaca de clase funcional iii de la nyha (new york heart association) y miocardiopatía no isquémica (genephit).

Type/Phase: II

Sponsored by: Asklepios Biopharmaceutical (Askbio).

Signature date: 16/07/2025

- **Moreno Gómez JR.** Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de la disminución de la lipoproteína (a) con pelacarsén (tqj230) en la progresión de la estenosis valvular aórtica calcificada.

Type/Phase: II

Sponsored by: Novartis Pharma Services Ag.

Signature date: 26/09/2025

- **Moreno Gómez JR.** Ensayo multicéntrico, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de omecamtiv mecarbilo en pacientes con insuficiencia cardíaca sintomática con fracción de eyección gravemente reducida.

Type/Phase: III

Sponsored by: Cytokinetics Inc.

Signature date: 21/04/2025

- **Moreno Gómez JR.** Estudio de fase 2, doble ciego, aleatorizado, controlado con placebo, de 4 grupos para estudiar los síntomas, la funcionalidad, la calidad de vida relacionada con la salud y la seguridad de la administración subcutánea repetida de ponegromab comparado con placebo en participantes adultos con insuficiencia cardíaca.

Type/Phase: II

Sponsored by: Pfizer Inc.

Signature date: 13/03/2025

- **Moreno Gómez JR.** Estudio de fase 3 controlado con placebo, aleatorizado, doble ciego que evalúa la eficacia y la seguridad de maridebart cafraglutida en la mortalidad y morbilidad en participantes con insuficiencia cardíaca con fracción de eyección conservada o levemente reducida y obesidad (maritime-hf).

Type/Phase: III

Sponsored by: Amgen Inc.

Signature date: 16/06/2025

- **Moreno Gómez JR.** Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de mk-0616 para reducir las complicaciones cardiovasculares graves en participantes con riesgo cardiovascular elevado.

Type/Phase: III

Sponsored by: Merck Sharp & Dohme LLC.

Signature date: 13/08/2025

- **Moreno Gómez JR.** Monotherapy with a p2y12 inhibitor followed by a direct-acting oral anticoagulant in patients with atrial fibrillation undergoing supraflexcruz coronary stent implantation (matrix-2).

Type/Phase: III

Sponsored by: Insel Gruppe Ag.

Signature date: 07/05/2025

- **Moreno Gómez JR.** Prospective, multicenter, randomized controlled trial to investigate the value of coronary ct angiography in the understanding an management of coronary calciun. the optimal trial.

Type/Phase: EOm prospectivo

Sponsored by: Fundación Epic.

Signature date: 27/11/2025

- **Moreno Gómez JR.** Registro prospectivo español mylead: alteraciones tardías y tempranas de la conducción inducidas por myval mylead spanish prospective registry: myval induced late and early conduction disturbances.

Type/Phase: OTROS

Sponsored by: Instituto De Estudios Ciencias Salud Castilla Instituto De Estudios Ciencias.

Signature date: 01/07/2025

- **Peinado Peinado R.** Reducción de descargas mediante ráfagas múltiples de estimulación antitaquicardia para taquicardias ventriculares rápidas en portadores de desfibrilador automático implantable.

Type/Phase: PRODUCTO SANITARIO

Sponsored by: Fundación Idibell.

Signature date: 07/02/2025

- **Rey Blas JR.** Eficacia y seguridad combinadas de una estrategia de tratamiento intensiva con finerenona y un inhibidor de sglt2 en pacientes hospitalizados con insuficiencia cardíaca (confirmation-hf).

Type/Phase: III

Sponsored by: CPC Clinical Research.

Signature date: 14/05/2025

- **Rey Blas JR.** Estudio pragmático, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia clínica de la finerenona en pacientes con insuficiencia cardíaca y fracción de eyección reducida que son intolerantes o no son aptos para el tratamiento con antagonistas esteroideos del receptor de mineralocorticoides (finality-hf).

Type/Phase: III

Sponsored by: CPC Clinical Research.

Signature date: 13/06/2025

- **Rodríguez Chaverri A.** Estudio de correlación del grado de congestión en insuficiencia cardíaca con el dispositivo sensocor.

Type/Phase: OTROS

Sponsored by: Ffdis.

Signature date: 12/05/2025

- **Rosillo Rodríguez S.** Arise RCT - a randomized controlled study of the neurescue device as an adjunct to advanced cardiac life support (acsl).

Type/Phase: PRODUCTO SANITARIO

Sponsored by: Neurescue Aps.

Signature date: 03/09/2025

- **Sanz Andrés A.** retirada del tratamiento neurohormonal en pacientes con miocardiopatía no isquémica, sin realce tardío de gadolinio y con test genético negativo, que hayan sido super-respondedores a la terapia de resincronización cardíaca.

Type/Phase:

Sponsored by: Fundación Idibell.

Signature date: 12/12/2025

Patents and trademarks

- **Riera del Moral LF, inventor; FIBHULP, assignee.** Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.
- **Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees.** Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.
- **Castro Conde A, author; FIBHULP, assignee.** Trade-mark name: RECAR Programa de Rehabilitación Cardíaca; CM 18457042; 2021 April 20.



- **Pérez Gómez AL, González Lafuente L, Pelegrín Vivancos P, Cuevas González S, Egea Maiquez J, Fernández Velasco M, Alquézar Burillo C, Bartolomé Robledo F, Ruiz Hurtado G; Hospital Universitario 12 de Octubre, Universidad de Murcia, FFIS-IMIB, FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario La Princesa.** Método de detección y cuantificación de motas extracelulares de ASC en muestras biológicas mediante citometría espectral. P202531231; 2025 Diciembre 22.